Tenax Therapeutics, Inc. (NASDAQ:TENX) Given Consensus Rating of “Moderate Buy” by Brokerages

Tenax Therapeutics, Inc. (NASDAQ:TENX) has received an average rating of “Moderate Buy” from the six ratings firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have given a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $29.6667.

Several equities research analysts recently issued reports on TENX shares. William Blair reiterated an “outperform” rating on shares of Tenax Therapeutics in a report on Tuesday, March 10th. Guggenheim boosted their price objective on Tenax Therapeutics from $25.00 to $34.00 and gave the company a “buy” rating in a report on Monday, March 16th. Cantor Fitzgerald started coverage on Tenax Therapeutics in a report on Tuesday, March 17th. They issued an “overweight” rating and a $35.00 price objective on the stock. Finally, Lifesci Capital upgraded Tenax Therapeutics to a “strong-buy” rating in a report on Thursday, March 12th.

Institutional Investors Weigh In On Tenax Therapeutics

Large investors have recently bought and sold shares of the stock. Boothbay Fund Management LLC purchased a new stake in Tenax Therapeutics during the 3rd quarter worth about $2,680,000. Quadrature Capital Ltd purchased a new stake in Tenax Therapeutics during the 4th quarter worth about $252,000. Corient Private Wealth LLC purchased a new stake in Tenax Therapeutics during the 4th quarter worth about $151,000. Virtu Financial LLC purchased a new stake in Tenax Therapeutics during the 3rd quarter worth about $92,000. Finally, Bank of America Corp DE increased its holdings in Tenax Therapeutics by 391.2% during the 1st quarter. Bank of America Corp DE now owns 18,569 shares of the specialty pharmaceutical company’s stock worth $297,000 after purchasing an additional 14,789 shares during the period. Hedge funds and other institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Trading Down 1.2%

TENX stock opened at $11.98 on Wednesday. The company has a market capitalization of $317.71 million, a PE ratio of -8.56 and a beta of 1.00. Tenax Therapeutics has a 12-month low of $5.34 and a 12-month high of $18.38. The business’s fifty day moving average price is $13.67 and its 200 day moving average price is $12.41.

Tenax Therapeutics (NASDAQ:TENX) last posted its quarterly earnings data on Tuesday, May 12th. The specialty pharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.05. Research analysts predict that Tenax Therapeutics will post -1.51 EPS for the current fiscal year.

About Tenax Therapeutics

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.